What is sarilumab?
Sarilumab is a monoclonal antibody approved for the treatment of polymyalgia rheumatica (PMR).
How does sarilumab work?
Sarilumab blocks the action of IL-6 – an immune system protein that drives inflammation. Tocilizumab is another drug that blocks IL-6 and is used in the treatment of Giant Cell Arteritis (GCA).
How is sarilumab given?
Sarilumab is given as a self-administered injection at a dose of 200 mg every 2 weeks.
Side effects:
We pay particular attention to liver function tests, lipids, and blood counts when using sarilumab.
All immunosuppressants require regular monitoring in the form of blood tests, in-person assessments, and vigilance for signs of infection.
